Supplemental Table 1: Effects on PD variables SPV, Body Sway, Adaptive Tracking Performance, and VAS subjective Alertness measured the next morning at 8 h post-dose following repeated-dose evening administration of 25 mg ACT-541468 to elderly subjects (data are maximum mean change from baseline ± SD; N = 8/2 for ACT-541468/placebo).

|  |  |  |  |
| --- | --- | --- | --- |
| **Assessment** | **Statistic** | **Day 2** | **Day 8** |
| **ACT-541-468** | **Placebo** | **ACT-541-468** | **Placebo** |
| **Saccadic Peak Velocity (SPV)****[degrees/sec]** | Mean | **-7.5** | **10.5** | **-2.5** | **-13.5** |
| SD | 34.5 | 5.9 | 46.3 | 15.8 |
| **Body Sway [mm]** | Mean | **-0.1** | **2.2** | **-0.1** | **5.9** |
| SD | 2.0 | 2.5 | 1.6 | 3.2 |
| **Adaptive Tracking [%]** | Mean | **-0.1** | **2.2** | **-0.1** | **-3.8** |
| SD | 2.0 | 2.5 | 1.6 | 3.2 |
| **VAS Bond and Lader - Alertness [%]** | Mean | **4.0** | **6.6** | **1.8** | **1.0** |
| SD | 14.6 | 8.4 | 4.9 | 0.2 |

# PD = pharmacodynamic; SD = standard deviation; SPV = saccadic peak velocity; VAS = visual analogue scale